First Page | Document Content | |
---|---|---|
Vaccines Papillomavirus Merck Combination drugs Merck & Co. Gadolinium Food and Drug Administration Lisinopril Nephrogenic systemic fibrosis Chemistry Pharmacology Medicine | FDA Patient Safety News: Show #54, August 2006Add to Reading ListSource URL: www.fda.govDownload Document from Source WebsiteFile Size: 123,18 KBShare Document on Facebook |
THE JOURNAL OF CHEMICAL PHYSICS 126, 181102 共2007兲 Ab initio simulation of a gadolinium-based magnetic resonance imaging contrast agent in aqueous solution Rodolphe Polleta兲 Laboratoire Francis Perrin, DSM/DRECAM/DocID: 1s1IP - View Document | |
Synthetic Phase Sensitive Inversion Recovery Late Gadolinium Enhancement from Post-contrast T1-mapping Shows Excellent Agreement with Conventional PSIR-LGE for Diagnosing Myocardial Scar Abdula G, Sörensson P, NickanderDocID: 1pN1h - View Document | |
Theranostics 2016, Vol. 6, Issue 10 Ivyspring International Publisher Research PaperDocID: 1oOeM - View Document | |
Current Version: 2.0 Revision Date: Sep 5, 2012 Material Safety Data Sheet Identity: GadoliniumDocID: 1oCb0 - View Document | |
Paper Formatting Instructions - MoDocID: 1nPdU - View Document |